They identified TET2 mutations in 27 of 354 MPN patients (7.6%), 29 of 69 CMML patients (42%), 11 of 91 AML patients (12%) and 1 of 28 M7 AML patients (3.6%). This evidence concerns the gene TET2 and myeloproliferative disorder.